行情

DVAX

DVAX

德纳维制药
NASDAQ

实时行情|Nasdaq Last Sale

9.26
-0.10
-1.06%
交易中 10:05 07/16 EDT
开盘
9.57
昨收
9.36
最高
9.83
最低
9.20
成交量
174.49万
成交额
--
52周最高
9.83
52周最低
1.800
市值
9.41亿
市盈率(TTM)
-5.3527
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测DVAX价格均价为15.33,最高价位20.00,最低价为12.00。

EPS

DVAX 新闻

更多
Dynavax Reports Collaboration With Mount Sinai To Develop Universal Flu Vaccine Candidate With CpG 1018 Adjuvant
Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Icahn School of Medicine at Mount Sinai (“Mount Sinai”) today
Benzinga · 1小时前
COVID-19 vaccine developers perk up on IMV rally
Premarket buying is lifting many COVID-19 vaccine players after IMV (NASDAQ:IMV) announced Health Canada sign-off on a Phase 1 study of its candidate DPX-C
seekingalpha · 1天前
Early-stage study underway on COVID-19 vaccine with Dynavax adjuvant
Dynavax Technologies (NASDAQ:DVAX) jumps 10% premarket on modest volume in reaction to its announcement that dosing is underway in a Phase 1 clinical trial
seekingalpha · 1天前
Why Dynavax's Stock Is Trading Higher Today
Dynavax Technologies (NASDAQ: DVAX) shares were trading higher on Tuesday after the company announced that the first participants were dosed with the company's coronavirus vaccine candidate the CpG 1018 Adjuvant in phase one clinical trial.
Benzinga · 1天前
Why Dynavax's Stock Is Trading Higher Today
Dynavax Technologies (NASDAQ: DVAX) shares were trading higher on Tuesday after the company announced that the first participants were dosed with the company's coronavirus vaccine candidate the CpG 1018 Adjuvant in phase one clinical trial.Dynavax Technologies
Benzinga · 1天前
Canada's Medicago begins human trials of plant-based COVID-19 vaccine
Reuters · 2天前
Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Medicago’s COVID-19 Vaccine Candidate with Dynavax’s CpG 1018 Adjuvant
* Medicago expects to enroll 180 healthy adult participants * Preliminary safety and immunogenicity results are expected in October 2020 * Dynavax is providing CpG 1018, the adjuvant contained in its U.S. FDA-approved adult hepatitis B vaccine, to enhance
GlobeNewswire · 2天前
Dynavax Technologies (DVAX) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Dynavax Technologies (DVAX) closed at $8.51, marking a -1.73% move from the previous day.
Zacks · 2天前

所属板块

生物技术和医学研究
-1.11%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

DVAX 简况

Dynavax Technologies Corporation是一家临床阶段的免疫治疗公司。该公司专注于通过Toll样受体(TLR)刺激平衡身体的先天和适应性免疫应答。该公司正研究其用于多种癌症适应症的候选产品,用作预防乙型肝炎疫苗和哮喘疾病的改善疗法。其产品包括HEPLISAV-B、AZD1419、SD-101、DV281、DV230F和DV1001。HEPLISAV-B是一种研究性成年乙型肝炎疫苗。用于治疗哮喘的AZD1419正处于开发阶段。SD-101是一种研究性TLR9激动剂,旨在产生对癌症有效并突出的免疫应答。DV281是一种研究性TLR9激动剂,专门用于向原发性肺肿瘤和肺转移瘤。DV230F用于治疗肝肿瘤。DV1001针对治疗多种恶性肿瘤的TLR 7和8激动剂。DV230F和DV1001正处于临床前开发阶段。
展开

微牛提供Dynavax Technologies Corporation(NASDAQ-DVAX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的DVAX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易DVAX股票基本功能。